| 11.74 0.41 (3.62%) | 10-02 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 15.48  |
1-year : | 17.27 |
| Resists | First : | 13.25 |
Second : | 14.78 |
| Pivot price | 11.64 |
|||
| Supports | First : | 10.77 | Second : | 8.96 |
| MAs | MA(5) : | 11.69 |
MA(20) : | 12.07 |
| MA(100) : | 11.17 |
MA(250) : | 6.57 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 41.3 |
D(3) : | 34 |
| RSI | RSI(14): 46.8 |
|||
| 52-week | High : | 15.88 | Low : | 1.38 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SLS ] has closed below upper band by 41.2%. Bollinger Bands are 75.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 12.02 - 12.11 | 12.11 - 12.17 |
| Low: | 11.23 - 11.31 | 11.31 - 11.38 |
| Close: | 11.62 - 11.76 | 11.76 - 11.87 |
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Sun, 04 Oct 2026
SLS Stock Rises Overnight: Traders Rally Behind Jim Cramer's 'Two Thumbs Up' Call Ahead Of Key AML Readout - stocktwits.com
Sun, 04 Oct 2026
SLS Short Interest Hits All-Time High: Sellas Bulls Smell A Short Squeeze As Executive Contract Changes Fuel Buyout Chatter - stocktwits.com
Sat, 03 Oct 2026
SELLAS Life Sciences Group (SLS) Following New SLS009 Data Is The Upside Still Priced In - Simply Wall Street
Fri, 02 Oct 2026
SLS Stock Gains Momentum: NVDA, MSFT Investor Loads Up Ahead Of AML Trial Milestone Trigger - stocktwits.com
Thu, 01 Oct 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS - PR Newswire
Thu, 01 Oct 2026
SELLAS Life Sciences Group, Inc. (SLS) stock price, news, quote and history - Yahoo Finance UK
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 202 (M) |
| Shares Float | 201 (M) |
| Held by Insiders | 0.9 (%) |
| Held by Institutions | 36.8 (%) |
| Shares Short | 56,370 (K) |
| Shares Short P.Month | 55,280 (K) |
| EPS | -0.22 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.68 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -23.3 % |
| Return on Equity (ttm) | -39.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -28 (M) |
| Levered Free Cash Flow | -16 (M) |
| PE Ratio | -53.37 |
| PEG Ratio | 0 |
| Price to Book value | 17.26 |
| Price to Sales | 0 |
| Price to Cash Flow | -83.43 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|